ABOUT THIS REPORT

The PD-L1 Market Insights Report evidences and discusses 8 key predictions for the PD-L1 testing space and illustrates how demand for PD-L1 testing will become the norm across most, if not all, of the tumor types under investigation within 2- 3 years. In addition it illustrates where the levels of investment in reimbursement, education, standardization and clarity of clinical utility essential to optimizing testing in support of that demand, will lag that demand, despite the fact that many, if not all the issues could have been anticipated.

This deck provides an overview of the full 60 slide reports. The report uses a case based reasoning methodology to help guide current and future investments related to PD-L1 testing. This proven method of problem solving and forward market predication, specifically for PD-L1, is based on an in depth and expert analysis of current and past trends of PD-L1 alongside our database of over 20 actionable companion and complementary biomarkers used in targeted therapy. Specific sources used include data from our Laboratory database and a panel of 30 US PD-L1/PD-1 prescribers surveyed on a regular basis, clinical trials database, annual reports, investor relations presentations, databases of news in the field and laboratory interactions.

early